Annuncio • Dec 02

Nukkleus Inc. (OTCPK:NUKK) completed the acquisition of Brilliant Acquisition Corporation (NasdaqCM:BRLI) from Nisun Investment Holding Limited and others in a reverse merger transaction.

Nukkleus Inc. (OTCPK:NUKK) signed a letter of intent to acquire Brilliant Acquisition Corporation (NasdaqCM:BRLI) from Nisun Investment Holding Limited and others in a reverse merger transaction on November 24, 2021. Nukkleus Inc. (OTCPK:NUKK) entered into an agreement to acquire Brilliant Acquisition Corporation(NasdaqCM:BRLI) from Nisun Investment Holding Limited and others for approximately $140 million in a reverse merger transaction on February 22, 2022. As a result of and upon the closing, all of the outstanding shares of Nukkleus Common Stock will be cancelled in exchange for the right to receive a pro -rata portion of 14,000,000 shares of Brilliant Common Stock. As per the terms of the transaction, Nukkleus will undertake a reverse stock split at a ratio of 1:25.146, or such other ratio as may be agreed between Nukkleus and Brilliant. On November 1, 2023, the parties entered into the first amendment to the plan of merger, to revise the exchange ratio from 1:26.227 to 1:35, reduce the closing payment shares issuable to existing holders of Nukkleus common stock from 14,000,000 shares to 10,500,000 shares, and revise the composition of the post -Business Combination board of directors. Upon completion of the merger agreement, Nukkleus would become the Nasdaq-listed parent company of Brilliant and trade under the ticker symbol “NUKK.", with former Nukkleus stockholders owning approximately 68.6% stake and former Brilliant shareholders owning approximately 34% stake of the ordinary shares of Brilliant Acquisition Corporation. Following the Business Combination, Nukkleus and Brilliant will operate as a combined company under the name Nukkleus Inc. The Merger Agreement provides that, promptly following the signing of the Merger Agreement, Nukkleus shall form a British Virgin Islands company and wholly owned subsidiary of Nukkleus. The transaction is subject to the following the receipt of the required approvals by Nukkleus’s and Brilliant’s shareholders, Nukkleus’s Registration Statement becoming effective, the approval of Nukkleus’s listing application, certain governmental approvals, the approval of the reverse stock split and Nukkleus having a gross amount of no less than $10 million in cash and cash equivalents available to it immediately after the closing, Brilliant’s unpaid debt, excluding certain transactions costs, not exceeding a threshold specified in the merger agreement, the domestication shall have been consummated and each of the additional agreements including the Registration Rights agreement, the Lock-Up agreements and the support agreements shall have been entered into and shall be in full force and effect. The transaction was unanimously approved by the Boards of Directors of Brilliant. The Board of Nukkleus also approved the business combination. Both Nukkleus’s and Brilliant’s board of directors unanimously recommended that holders of their common stock vote in favor of the proposal. The deal is expected to close in the second quarter of 2022. As of March 22, 2022, Brilliant announced that it has extended the period of time it will have to consummate its initial business combination by a further four months, or until July 23, 2022. As of July 19, 2022, Brilliant announced that it has extended the period of time to consummate its initial business combination by a further four months, or until October 23, 2022. As of October 17, 2022, the shareholders of Brilliant approved to extend the period of time it will have to consummate its initial business combination until November 23, 2022 or until January 23, 2023. As of January 25, 2023, Brilliant has extended the period of time to consummate its initial business combination until February 23, 2023. As of February 23, 2023, Brilliant has extended the period of time to consummate its initial business combination until March 23, 2023. In connection with the monthly extension to February 23, 2023, The shareholder approval also permits Brilliant to further extend Brilliant’s initial business combination deadline up to a further one month, or until April 23, 2023. As of March 21, 2023, Brilliant announced that it has extended the period to consummate its initial business combination until April 23, 2023. Nukkleus intends to use the proceeds from the transaction to accelerate growth across Nukkleus’s network, empowering Nukkleus’s portfolio of businesses to pioneer faster and more valuable custody. As of March April 5, 2023, Brilliant Acquisition Corporation shareholder meeting will be held on April 17, 2023, to discuss the transition. Special Meeting will be to consider and vote upon the following proposals, the proposal announced by Brilliant that it has extended the period of time it will have to consummate its initial business combination from April 23, 2023 to July 23, 2023. If the Extension Amendment and the Adjournment proposals are not approved and we do not consummate a business combination by April 23, 2023, will cease all operations except for the purpose of winding up, as promptly as reasonably possible but no more than five business days thereafter, redeem 100% of the outstanding public shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account. As of April 21, 2023, Brilliant has extended the period of time to consummate its initial business combination until May 23, 2023. As of Jun 16, 2023, the Brilliant Acquisition filled a proxy statement to conduct a special meeting of shareholders for the extension approval of initial business combination from July 23, 2023 to up to not later than December 23, 2023. As of August 23, Brilliant announced that it has extended the period of time it will have to consummate its initial business combination until September 23, 2023. On October 20, 2023, the business combination completion window is extended until November 23, 2023. ClearThink Capital LLC acted as the exclusive financial advisor and Ralph De Martino of Schiff Hardin LLP acted as legal advisor to Nukkleus. Axiom Capital Management Inc., EarlyBirdCapital, Inc. and Red Eight Capital Limited acted as financial advisors and Giovanni Caruso of Loeb & Loeb LLP acted as legal advisor to Brilliant. Mark Zimkind of Continental Stock Transfer & Trust Company acted as transfer agent and registrar to Brilliant Acquisition Corporation. Issuer Direct Corporation (NYSEAM:ISDR) acted as transfer agent and registrar to Nukkleus. ArentFox Schiff, Axiom, Red Eight Capital and Loeb & Loeb also provided due diligence services. Ralph V. De Martino, Robert J. Minkus and Andrew M. Banks of ArentFox Schiff LLP acted as legal advisors to Nukkleus. The Benchmark Company, LLC acted as financial advisor and fairness opinion provider to Brilliant Board. Karen Smith of Advantage Proxy, Inc. acted as proxy solicitor to Brilliant and Nukkleus and received a fee of $10,000, plus disbursements from Brilliant and $5,000 from Nukkleus. Brilliant has agreed to pay Benchmark for their services in connection with the Business Combination an aggregate fee of up to $400,000, of which (a) $50,000 being paid to Benchmark upon the execution of the engagement letter among the parties, and an additional $350,000 being paid to Benchmark upon the earlier of the closing of the Business Combination and August 15, 2022. As of June 30, 2023, Nukkleus has paid ClearThink $140,000 and upon closing of the Business Combination Nukkleus is obligated to pay ClearThink 1.2% of the total transaction value plus reimbursable expenses less the $140,000 paid to Clear Think to date. Brilliant will pay EarlyBirdCapital a cash fee equal to 1.0% of the total consideration payable in a Business Combination if EarlyBirdCapital introduces Brilliant to the target business with which Brilliant completes a Business Combination. Nukkleus Inc. (OTCPK:NUKK) completed the acquisition of Brilliant Acquisition Corporation (NasdaqCM:BRLI) from Nisun Investment Holding Limited and others in a reverse merger transaction on November 30, 2023.

Banks crescita degli utili	8.3%
Tasso di crescita dei ricavi	2.4%
Rendimento futuro del capitale proprio	12.41%
Copertura analitica	Good
Ultimo aggiornamento	16 Jun 2026

Data	Ricavi	Utili	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
3/31/2029	4,690,752	1,568,255	N/A	N/A	5
3/31/2028	4,403,855	1,497,352	N/A	N/A	8
3/31/2027	3,976,257	1,335,926	N/A	N/A	8
3/31/2026	4,401,824	1,248,632	-6,311,262	-5,992,524	N/A
12/31/2025	4,017,830	1,049,949	N/A	N/A	N/A
9/30/2025	3,959,355	1,009,239	N/A	N/A	N/A
6/30/2025	3,891,114	886,654	N/A	N/A	N/A
3/31/2025	3,898,840	885,433	-6,093,001	-5,748,181	N/A
12/31/2024	3,834,387	892,047	N/A	N/A	N/A
9/30/2024	3,583,727	829,381	-1,508,715	-1,206,202	N/A
6/30/2024	3,300,875	723,101	N/A	N/A	N/A
3/31/2024	3,122,105	678,993	-554,280	-298,509	N/A
12/31/2023	3,010,015	654,570	N/A	N/A	N/A
9/30/2023	3,197,943	637,316	13,193,557	13,401,234	N/A
6/30/2023	2,861,070	641,425	N/A	N/A	N/A
3/31/2023	2,779,216	555,527	2,078,659	2,261,835	N/A
12/31/2022	2,940,436	595,100	N/A	N/A	N/A
9/30/2022	2,626,161	478,786	-6,898,903	-6,735,131	N/A
6/30/2022	2,844,665	439,232	N/A	N/A	N/A
3/31/2022	2,805,932	530,479	2,183,600	2,322,381	N/A
12/31/2021	2,515,381	595,272	N/A	N/A	N/A
9/30/2021	2,473,253	641,154	6,697,952	6,884,561	N/A
6/30/2021	2,433,275	599,186	N/A	N/A	N/A
3/31/2021	2,455,289	471,020	12,157,843	12,374,003	N/A
12/31/2020	2,457,443	399,009	N/A	N/A	N/A
9/30/2020	2,441,861	376,423	1,764,615	2,004,408	N/A
6/30/2020	2,439,203	408,505	N/A	N/A	N/A
3/31/2020	2,411,712	448,568	-6,431,197	-6,197,490	N/A
12/31/2019	2,559,370	90,600	N/A	N/A	N/A
9/30/2019	2,450,143	24,874	N/A	-10,570,257	N/A
6/30/2019	2,545,036	97,989	N/A	N/A	N/A
3/31/2019	2,555,627	96,566	N/A	-5,442,855	N/A
12/31/2018	2,596,730	510,773	N/A	N/A	N/A
9/30/2018	2,769,420	619,262	N/A	1,464,012	N/A
6/30/2018	2,809,851	619,272	N/A	N/A	N/A
3/31/2018	2,715,720	576,547	N/A	-3,204,611	N/A
12/31/2017	2,748,252	574,592	N/A	N/A	N/A
9/30/2017	2,725,006	562,006	N/A	-8,825,487	N/A
6/30/2017	2,620,532	589,195	N/A	N/A	N/A
3/31/2017	2,676,935	603,544	N/A	-9,390,592	N/A
12/31/2016	2,669,318	655,118	N/A	N/A	N/A
9/30/2016	2,640,981	643,939	N/A	-4,957,942	N/A
6/30/2016	2,666,436	643,136	N/A	N/A	N/A
3/31/2016	2,759,921	668,514	N/A	-1,465,540	N/A
12/31/2015	2,792,215	601,850	N/A	N/A	N/A
9/30/2015	2,817,118	634,493	N/A	-1,463,378	N/A
6/30/2015	2,901,102	610,319	N/A	N/A	N/A

Dati	Ultimo aggiornamento (ora UTC)
Analisi dell'azienda	2026/06/16 02:57
Prezzo dell'azione a fine giornata	2026/06/16 00:00
Utili	2026/03/31
Utili annuali	2026/03/31

Pacchetto	Dati	Tempistica	Esempio Fonte USA ^*
Dati finanziari della società	10 anni	Conto economico Rendiconto finanziario Bilancio	Modulo SEC 10-K Modulo SEC 10-Q
Stime di consenso degli analisti	+3 anni	Previsioni finanziarie Obiettivi di prezzo degli analisti	Rapporti di ricerca degli analisti Blue Matrix
Prezzi di mercato	30 anni	Prezzi delle azioni Dividendi, scissioni e azioni	Dati di mercato ICE Modulo SEC S-1
Proprietà	10 anni	Top azionisti Insider trading	Modulo 4 SEC Modulo 13D SEC
Gestione	10 anni	Team di leadership Consiglio di amministrazione	Modulo SEC 10-K Modulo SEC DEF 14A
Sviluppi principali	10 anni	Annunci aziendali	Modulo 8-K SEC

Analista	Istituzione
Shinichi Tamura	Barclays
Shinichiro Nakamura	BofA Global Research
Koichi Niwa	Citigroup Inc

Mizuho Financial Group Crescita futura

Criteri Future verificati 1/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Mizuho Financial Group, Inc. Provides Earnings Guidance for the Fiscal Year Ending March 31, 2026

Mizuho Financial Group, Inc. Revises Consolidated Earnings Guidance for the Fiscal Year 2025 Ending March 31, 2026

Mizuho Financial Group, Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2025

Recent updates

Mizuho Financial Group, Inc. to Report Q1, 2027 Results on Jul 30, 2026

Mizuho Financial Group, Inc., Annual General Meeting, Jun 26, 2026

Mizuho Financial Group, Inc. (TSE:8411) announces an Equity Buyback for 25,000,000 shares, representing 1.03% for ¥100,000 million.

Mizuho Financial Group, Inc. to Report Fiscal Year 2026 Results on May 15, 2026

Mizuho Financial Group, Inc. Announces Changes in Board Roles and Executive, Effective April 1, 2026

Mizuho Financial Group, Inc. Provides Earnings Guidance for the Fiscal Year Ending March 31, 2026

Mizuho Financial Group, Inc. Appoints Ahmed Siddiqi as Regional Head of Corporate Investment Bank for the Middle East, Africa, Turkiye and Central Asia Caucasus

Mizuho Financial Group, Inc. to Report Q3, 2026 Results on Feb 02, 2026

Mizuho Financial Group, Inc. Announces Dividend for the Second Quarter Ended September 30, 2025, Commencement of Dividend Payment (Scheduled) on December 5, 2025

Mizuho Financial Group, Inc. (TSE:8411) announces an Equity Buyback for 60,000,000 shares, representing 2.41% for ¥200,000 million.

Mizuho Financial Group, Inc. Announces Board Changes, Effective November 30, 2025

Mizuho Financial Group, Inc. Announces Management Appointments

Semnur Pharmaceuticals, Inc. completed the acquisition of Denali Capital Acquisition Corp. (NasdaqGM:DECA) from a group of shareholders in a reverse merger transaction.

Mizuho Financial Group, Inc. to Report Q2, 2026 Results on Nov 14, 2025

Mizuho Financial Group, Inc. Revises Consolidated Earnings Guidance for the Fiscal Year 2025 Ending March 31, 2026

Mizuho Securities Co., Ltd., Mizuho Financial Group, Inc. (TSE:8411) and Mizuho International plc agreed to acquire Augusta & Co. plc.

Hotel 101 Global Pte. Ltd completed the acquisition of JVSPAC Acquisition Corp. (NasdaqCM:JVSA) from Winky Investments Limited, AQR Capital Management, LLC, Meteora Capital, LLC, Mizuho Financial Group, Inc. (TSE:8411) and others in reverse merger transaction.

Scage International Limited completed the acquisition of Finnovate Acquisition Corp. (NasdaqGM:FNVT) from a group of shareholders in a reverse merger transaction.

Mizuho Financial Group, Inc. to Report Q1, 2026 Results on Jul 31, 2025

Mizuho Is Said to Be on Cusp of Buying Indian Investment Bank Avendus

Namib Minerals completed the acquisition of Hennessy Capital Investment Corp. VI (NasdaqGM:HCVI) from a group of shareholders in a reverse merger transaction.

Mizuho Financial Group, Inc. (TSE:8411) announces an Equity Buyback for 40,000,000 shares, representing 1.59% for ¥100,000 million.

Mizuho Financial Group, Inc., Annual General Meeting, Jun 24, 2025

Webull Corporation completed the acquisition of SK Growth Opportunities Corporation (NasdaqGM:SKGR) from a group of shareholders in a reverse merger transaction.

Class Over Inc. completed the acquisition of Battery Future Acquisition Corp. (NYSE:BFAC) from a group of shareholders in a reverse merger transaction.

Mizuho Financial Group, Inc. to Report Fiscal Year 2025 Results on May 15, 2025

Femco Steel Technology Co., Ltd. (TPEX:6731) completed the acquisition of Chenghe Acquisition I Co. (NasdaqGM:LATG) from a group of sellers in a reverse merger transaction.

TVS Credit Reportedly to Make A Bid for Avendus Capital

New Era Helium Corp. completed the acquisition of Roth Ch Acquisition V Co. (NasdaqGM:ROCL) from a group of sellers in a reverse merger transaction.

Mizuho Financial Group, Inc. to Report Q3, 2025 Results on Feb 03, 2025

Mizuho Financial Group, Inc. (TSE:8411) completed the acquisition of 14.99% stake in Rakuten Card Co.,Ltd. from Rakuten Group, Inc. (TSE:4755).

Mizuho Financial Group, Inc. (TSE:8411) agreed to acquire 14.99% stake in Rakuten Card Co.,Ltd. from Rakuten Group, Inc. (TSE:4755) for approximately ¥170 billion.

Mizuho Financial Group, Inc. (TSE:8411) announces an Equity Buyback for 50,000,000 shares, representing 1.97% for ¥100,000 million.

Nomura Holdings and Mizuho Financial Group Reportedly Leading Bidders for Avendus Capital

Carlyle, Mizuho & Premji Invest Reportedly Aim for Avendus

Mizuho Financial Group, Inc. to Report Q2, 2025 Results on Nov 14, 2024

Citius Oncology, Inc. completed the acquisition of TenX Keane Acquisition (NasdaqGM:TENK) from 10XYZ Holdings LP, Hudson Bay Capital Management LP, Wolverine Asset Management, LLC, Mizuho Financial Group, Inc. and others in a reverse merger transaction.

Mizuho Reportedly Plans to Say No to Yes Bank Deal

Mizuho Financial Group, Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2025

Semnur Pharmaceuticals, Inc. signed a letter of intent to acquire Denali Capital Acquisition Corp. (NasdaqGM:DECA) in a reverse merger transaction for approximately $2 billion on July 2, 2024.

Mizuho Financial Group, Inc. to Report Q1, 2025 Results on Jul 31, 2024

Mizuho Financial Reportedly in Talks to Buy KKR’s Part Stake in InCred Finance

Class Over Inc. entered into a definitive business combination agreement to acquire Battery Future Acquisition Corp. (NYSE:BFAC) in a reverse merger transaction.

Mizuho Financial Group, Inc. to Report Fiscal Year 2024 Results on May 15, 2024

Nature's Miracle Inc. completed the acquisition of Lakeshore Acquisition II Corp. (NasdaqGM:LBBB) from a group of shareholders in a reverse merger transaction.

Ethereal Tech PTE. Ltd (BitFuFu) acquired Arisz Acquisition Corp. (NasdaqGM:ARIZ) from a group of shareholders in a reverse merger transaction.

SK Growth Opportunities Corporation (NasdaqGM:SKGR) agreed to acquire Webull Corporation.

Mizuho Financial Group, Inc. Announces Change in Representative Executive Officer

Adagio Medical, Inc. entered a definitive agreement to acquire ARYA Sciences Acquisition Corp IV (NasdaqCM:ARYD) from ARYA Sciences Holdings IV, Perceptive Advisors LLC and Others for $26.736 million.

Mizuho Financial Group, Inc. Provides Year End Dividend Guidance for the Fiscal Year Ending March 31, 2024

Mizuho Financial Group, Inc. to Report Q3, 2024 Results on Feb 02, 2024

Ecohouse Developments Limited entered into definitive business combination agreement to acquire Zalatoris II Acquisition Corp. from J.Streicher Holdings LLC and others for approximately $130 million in a reverse merger transaction.

Nukkleus Inc. (OTCPK:NUKK) completed the acquisition of Brilliant Acquisition Corporation (NasdaqCM:BRLI) from Nisun Investment Holding Limited and others in a reverse merger transaction.

Mizuho Financial Group, Inc. Revises Interim Dividend for the Six Months Ended September 30, 2023, Payable on December 6, 2023; Revises Year End Dividend Guidance for the Fiscal Year Ending March 31, 2024

Mizuho Financial Group Reportedly Plans to increase its Stake in Rakuten Securities to Nearly 50% with an Expected Investment of about JPY 90 Billion

Citius Oncology, Inc. entered into an agreement and plan of merger to acquire TenX Keane Acquisition (NasdaqGM:TENK) from 10XYZ Holdings LP and others for approximately $730 million in a reverse merger transaction.

Mizuho Financial Group, Inc. to Report Q2, 2024 Results on Nov 13, 2023

Golden Star Acquisition Corporation (NasdaqGM:GODN) entered into a definitive business combination agreement to acquire Gamehaus Network Technology Co.,Ltd.

two (NYSE:TWOA) entered into a definitive business combination agreement to acquire LatAm Logistic Properties, S.A.

Environmental Solutions Group Holdings Limited acquired Genesis Unicorn Capital Corp. (NasdaqGM:GENQ) from a group of shareholders in a reverse merger transaction.

Mizuho Financial Group Inc Hires Jeff Jaenicke as Managing Director and Head of Private - Equity Lp Fund Financing

Mizuho Financial Group, Inc. Provides Dividend Guidance for the Second Quarter and Fiscal Year Ending March 31, 2024

Verde Bioresins, Inc. entered into a definitive business combination agreement to acquire TLGY Acquisition Corporation (NasdaqGM:TLGY) from TLGY Sponsors LLC and other for approximately $780 million in a reverse merger transaction.

Mizuho Financial Group, Inc. to Report Q1, 2024 Results on Jul 31, 2023

Kustom Entertainment, Inc. entered into a merger agreement to acquire Clover Leaf Capital Corp. (NasdaqCM:CLOE) for approximately $130 million in a reverse merger transaction.

Mizuho Financial Group, Inc., Annual General Meeting, Jun 23, 2023

Ocean Biomedical, Inc. completed the acquisition of Aesther Healthcare Acquisition Corp. (NasdaqGM : AEHA) from a group of shareholders in a reverse merger transaction.

Mizuho Financial Group, Inc. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2023

Longevity Biomedical, Inc. entered into an agreement to acquire Denali Capital Acquisition Corp. (NasdaqGM:DECA) from Denali Capital Global Investments LLC and others for approximately $130 million in a reverse merger transaction.

Mizuho Financial Group, Inc. to Report Q3, 2023 Results on Feb 02, 2023

Previsioni di crescita degli utili e dei ricavi

Previsioni di crescita futura degli analisti